RESEARCH_Immunotherapty copy

The Food and Drug Administration (FDA) has granted an accelerated approval to Keytruda (pembrolizumab) for use in combination with chemotherapy as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer (NSCLC), regardless of PD-L1 expression.

Read more: http://www.curetoday.com/articles/fda-approves-keytruda-combo-for-lung-cancer